Company Analysis

Veradermics, Incorporated (MANE)

NYSE: MANE · Pharmaceutical Preparations · New Haven, CT · filing with the SEC since 2020
Grade5.7
◀ Past 6.8● Present 6.4▶ Future 4.4
7 est.

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

3 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Veradermics, Incorporated’s names, not what it holds today.

Patents granted
3
3 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 1 in 2024 and none in 2023
Applications published
34
28 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'21'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals2
Medical technology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Veradermics, Incorporated its own name
named as the applicant on its applications, in US
0 granted
33 published
VERADERMICS, INCORPORATED its own name
US, as the owner printed on each patent
3 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 9, 202512,491,184Compositions and methods of use for modified release minoxidilPharmaceuticalsVERADERMICS, INCORPORATED
Apr 8, 202512,268,688Compositions and methods of use for modified release minoxidilPharmaceuticalsVERADERMICS, INCORPORATED
Jun 11, 202412,005,220Microneedle patch for immunostimulatory drug deliveryMedical technologyVERADERMICS, INCORPORATED
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0387394COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDILPharmaceuticalsVeradermics, Incorporated
Dec 18, 20252025/0381186COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDILPharmaceuticalsVeradermics, Incorporated
Dec 11, 20252025/0375448COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDILPharmaceuticalsVeradermics, Incorporated
Dec 4, 20252025/0367200COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDILPharmaceuticalsVeradermics, Incorporated
Dec 4, 20252025/0367199COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDILPharmaceuticalsVeradermics, Incorporated
Dec 4, 20252025/0367198COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDILPharmaceuticalsVeradermics, Incorporated
Dec 4, 20252025/0367197COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDILPharmaceuticalsVeradermics, Incorporated
Dec 4, 20252025/0367196COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDILPharmaceuticalsVeradermics, Incorporated
Dec 4, 20252025/0367195COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDILPharmaceuticalsVeradermics, Incorporated
Dec 4, 20252025/0367194COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDILPharmaceuticalsVeradermics, Incorporated
What it applied for, 2024 to 2025: Pharmaceuticals 32 · Medical technology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton MANE · research, not advice